title: Is spironolactone safe for dialysis patients?
abstract: BACKGROUND
  Spironolactone is useful in heart failure, but is not given to dialysis patients for fear of hyperkalaemia. This study evaluated the safety of spironolactone administration in haemodialysis patients.
  
  
  METHODS
  Fifteen haemodialysis outpatients with mean serum potassium <5.6 mEq/l over the preceding 4 months were treated with spironolactone 25 mg daily for 28 days. Serum potassium was measured before every haemodialysis during the study. Aldosterone and renin were measured at the beginning and end of the study. Patients were monitored for side effects. Data were examined with a paired t-test, with patients serving as their own controls and P < 0.05 considered significant. A sample size of 14 was required to achieve a power of 0.8 and a P = 0.05 to detect a potassium difference of 0.5 +/- 0.6 mEq/l. All patients were analysed as intention-to-treat.
  
  
  RESULTS
  The mean potassium level was 4.6 +/- 0.6 mEq/l at baseline and 4.9 +/- 0.9 mEq/l at study completion (P = 0.14). Thirteen patients completed the trial with no potassium levels >6.0 mEq/l. Four patients had potassium levels between 5.5 and 6.0 mEq/l. One patient was withdrawn at day 20 after developing hyperkalaemia (7.6 mEq/l). Another patient was withdrawn at day 25 after missing a dialysis treatment. There were no differences in either baseline or 28 day aldosterone or renin levels (16.8 +/- 28.8 vs 11.7 +/- 6.1 ng/dl and 3.5 +/- 3.9 vs 3.5 +/- 3.5 ng/ml/h, respectively). Infrequent side effects included dry mouth, nosebleed, pruritus, gynecomastia and diarrhoea. No significant leukopenia or anaemia was noted.
  
  
  CONCLUSIONS
  Spironolactone may be considered as a treatment option for selected chronic haemodialysis patients with heart disease.
authors.affiliation: Division of Nephrology and Hypertension, West Penn Allegheny Health System, Allegheny General Hospital, Pittsburgh, PA, USA.
authors.forename: Shahid
authors.initials: S
authors.lastname: Hussain
authors.forename: Darren E
authors.initials: DE
authors.lastname: Dreyfus
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Marcus
authors.forename: Robert W W
authors.initials: RW
authors.lastname: Biederman
authors.forename: Rita L
authors.initials: RL
authors.lastname: McGill
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000450:Aldosterone / Q000097:blood; D005260:Female; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects*; D011188:Potassium / Q000097:blood; D006435:Renal Dialysis; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D012083:Renin; D011188:Potassium